

Supporting Information

Synthesis, crystal structures, anticancer activities and molecular docking studies of novel thiazolidinone Cu(II) and Fe(III) complexes targeting lysosomes: special emphasis on their binding to DNA/BSA

Jia Shao,^{†a} Qiang Zhang,^{†b} Jing Wei,^c Zhiguang Yuchi,^c Peng Cao,^d Shao-Qing Li,^b Shan Wang,^a Jing-Yuan Xu,^e Shuang Yang,^f Yi Zhang,^{*a} Jin-Xia Wei^{*g} and Jin-Lei Tian^{*b}

a. Department of Pharmacy, Tianjin First Central Hospital, Tianjin 300192, P. R. China.

b. College of Chemistry, Nankai University, Tianjin 300071, P. R. China.

c. Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, Collaborative Innovation Center of Chemical Science and Engineering, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, P. R. China.

d. Key Laboratory of Drug Targets and Drug Leads for Degenerative Diseases, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China.

e. School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.

f. Medical College of Nankai University, Tianjin 300071, P. R. China.

g. School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, Tianjin 300617, P. R. China.

†These authors contributed equally to this work.

*Email: tiant@nankai.edu.cn; wing_zh1821@sina.com; weijinxia19871017@163.com.

Figure captions:

Figure S1 IR of $[\text{Cu}(\text{L})_2\text{Cl}]\cdot\text{Cl}\cdot\text{H}_2\text{O}$ (**1**).

Figure S2 IR of $[\text{Fe}(\text{L})_2\text{Cl}_2]\cdot\text{Cl}\cdot\text{MeOH}\cdot\text{CHCl}_3\cdot\text{H}_2\text{O}$ (**2**).

Figure S3 ESI-MS spectrum of $[\text{Cu}(\text{L})_2\text{Cl}]\cdot\text{Cl}\cdot\text{H}_2\text{O}$ (**1**).

Figure S4 ESI-MS spectrum of $[\text{Fe}(\text{L})_2\text{Cl}_2]\cdot\text{Cl}\cdot\text{MeOH}\cdot\text{CHCl}_3\cdot\text{H}_2\text{O}$ (**2**).

Figure S5 Absorption spectral traces of **1** (A) and **2** (B) in PBS at different times (0, 3, 6 and 12 h).

Figure S6 Fluorescence spectra of BSA in the different concentrations of **1** (A) and **2** (B) at 298 K. The concentrations of BSA (0.3 μM), complex **1** and **2** (0-0.97 μM).

Figure S7 Plot of $\text{Log}[(F_0 - F)/F]$ versus $\text{Log}[Q]$.

Table S1 Comparison of DNA binding between analogues.

Table S2 Comparison of BSA binding between analogues.

Table S3 IC_{50} values (μM) obtained with different cell lines for 48 h.




Figure S1 IR spectrum of $[\text{Cu}(\text{L})_2\text{Cl}] \cdot \text{Cl} \cdot \text{H}_2\text{O}$ (1).




Figure S2 IR spectrum of $[\text{Fe}(\text{L})_2\text{Cl}_2] \cdot \text{Cl} \cdot \text{MeOH} \cdot \text{CHCl}_3 \cdot \text{H}_2\text{O}$ (2).




Figure S3 ESI-MS spectrum of [Cu(L)₂Cl]·Cl·H₂O (**1**).




Figure S4 ESI-MS spectrum of [Fe(L)₂Cl₂]·Cl·MeOH·CHCl₃·H₂O (**2**).




Figure S5 Absorption spectral traces of **1** (A) and **2** (B) in PBS at different times (0, 3, 6 and 12 h).




Figure S6 Fluorescence spectra of BSA in the different concentrations of **1** (A) and **2** (B) at 298 K. The concentrations of BSA (0.3 μ M), complex **1** and **2** (0-0.97 μ M).




Figure S7 Plot of $\text{Log}[(F_0 - F)/F]$ versus $\text{Log}[Q]$.

Table S1 Comparison of DNA binding between analogues.

Compound	$K_{sv} \times 10^3 (\text{M}^{-1})$	$K_b \times 10^4 (\text{M}^{-1})$	$K_{app} \times 10^5 (\text{M}^{-1})$
Jia Shao (2021)			
$[\text{CuL}_2\text{Cl}]\text{Cl} \cdot \text{H}_2\text{O}$ (1)	5.98	8	2.40
$[\text{FeL}_2\text{Cl}_2]\text{Cl} \cdot \text{MeOH} \cdot \text{CHCl}_3 \cdot \text{H}_2\text{O}$ (2)	16.2	11.5	6.49
Surbhi Jain (2020)³⁷			
$[\text{Cu}(\text{L1})(\text{phen})](\text{ClO}_4)_2$	3.37	0.585	6.12
$[\text{Cu}(\text{L1})_2](\text{ClO}_4)_2$	2.90	0.263	5.07
$[\text{Cu}(\text{L1})(\text{bipy})](\text{ClO}_4)_2 \cdot \text{H}_2\text{O}$	2.54	0.101	4.38
$[\text{Cu}(\text{L1})(\text{imd})(\text{ClO}_4)](\text{ClO}_4)$	2.50	0.212	4.41
Nuno M. R. Martins (2017)³⁹			
$[\text{Cu}(1_K N, O^2: 2_K O\text{-HL}^1)(\text{CH}_3\text{OH})]_2$	569 ± 20	27.2 ± 1.9	15.1
$[\text{Cu}(1_K N, O^2: 2_K O\text{-HL}^1)((\text{CH}_3)_2\text{NCHO})]_2$	596 ± 23	33.5 ± 2.1	16.0
$[\text{Cu}(\text{K} N\text{-HL}^1)\text{-}(\text{en})_2] \text{CH}_3\text{OH} \cdot \text{H}_2\text{O}$	286 ± 12	17.2 ± 3.2	8.9
$[\text{Fe}(\text{K} N^3\text{-HL}^2)_2]$	346 ± 13	19.8 ± 2.6	9.5

Jessica Palmucci (2016)⁴⁰

[Cu(H ₂ L ¹)(H ₂ O)(im)]·3H ₂ O	11.73 ± 0.12	0.176 ± 0.034	5.86
[Cu(H ₂ L ³)(im) ₂]·H ₂ O	5.42 ± 0.30	0.085 ± 0.021	2.71

Kang Zheng (2015)⁴¹

[Cu ₂ (chpoxd)(H ₂ O)(bpy)](NO ₃)·C ₂ H ₅ OH·H ₂ O	-	25.9 ± 8.8	8.33 ± 0.33
[Cu ₂ (chmpoxd)-(H ₂ O)(bpy)]Cl·3H ₂ O	-	13.8 ± 5.2	6.25 ± 0.23

Xue-Quan Zhou (2015)⁴²

[CuL ² Cl]ClO ₄	-	86.8	2.08
[CuL ² (acac)]PF ₆	-	49.7	2.15
[CuL ^{2(R)} Cl] ₂ (PF ₆) ₂	-	58.7	1.24
[CuL ^{2(S)} Cl] ₂ (PF ₆) ₂	-	173	1.26
[CuL ^{2(R)} (acac)]PF ₆	-	115	2.09
[CuL ^{2(S)} (acac)]PF ₆	-	346	2.18

Kang Zheng (2014)³⁸

[Cu ₂ (pdmaox)Cl(CH ₃ OH)(dabt)] CH ₃ OH	95.9	8.35	-
[Cu ₂ (pdmaox)(bpy)(H ₂ O)]-(pic)·H ₂ O	56.9	3.39	-

Table S2 Comparison of BSA binding between analogues.

Compound	$K_{av} \times 10^5 (M^{-1})$	$K_q \times 10^{13} (M^{-1}S^{-1})$	$K_b \times 10^5 (M^{-1})$	n
Jia Shao (2021)				
[CuL ₂ Cl]Cl·H ₂ O (1)	2.33	3.76	0.4	0.87
[FeL ₂ Cl ₂]Cl·MeOH·CHCl ₃ ·H ₂ O (2)	2.71	4.37	0.7	0.91
Surbhi Jain (2020)³⁷				
[Cu(L)(phen)](ClO ₄) ₂	1.73	1.73	1.18	1.18 ± 0.07
[Cu(L) ₂](ClO ₄) ₂	3.04	3.04	1.81	1.08 ± 0.07
[Cu(L)(bipy)](ClO ₄) ₂ ·H ₂ O	2.30	2.30	1.40	1.135 ± 0.007
[Cu(L)(imd)](ClO ₄)](ClO ₄)	1.40	1.40	1.08	1.10 ± 0.008
Nuno M. R. Martins (2017)³⁹				
[Cu(1 κ N,O ² :2 κ O-HL ¹)(CH ₃ OH)] ₂	11.6 ± 0.6	11.6	9.7±1	~1
[Cu(1 κ N,O ² :2 κ O-HL ¹)((CH ₃) ₂ NCHO)] ₂	15.4 ± 0.7	15.4	11.9±0.9	~1
[Cu(κ N-HL ¹)-(en) ₂] CH ₃ OH·H ₂ O	2.2 ± 0.1	2.2	5.0 ± 0.1	~1
[Fe(κ N ³ -HL ²) ₂]	6.0 ± 0.3	6.6	10.6 ± 0.8	~1
Jessica Palmucci (2016)⁴⁰				
[Cu(H ₂ L ¹)(H ₂ O)(im)]·3H ₂ O	1.048 ± 0.022	1.04 ± 0.02	-	-
[Cu(H ₂ L ³)(im) ₂]·H ₂ O	2.964 ± 0.085	2.96 ± 0.08	-	-
Kang Zheng (2015)⁴¹				
[Cu ₂ (chpoxd)(H ₂ O)(bpy)](NO ₃)·C ₂ H ₅ OH·H ₂ O	-	-	-	-
[Cu ₂ (chmpoxd)-(H ₂ O)(bpy)]Cl·3H ₂ O	-	-	-	-
Xue-Quan Zhou (2015)⁴²				
[CuLi ¹ Cl]ClO ₄	0.119	-	0.208	1.0
[CuLi ¹ (acac)]PF ₆	0.170	-	0.153	0.99
[CuLi ^{2(R)} Cl] ₂ (PF ₆) ₂	0.125	-	0.203	1.10
[CuLi ^{2(S)} Cl] ₂ (PF ₆) ₂	0.133	-	1.28	1.25

$[\text{CuLi}^{2(R)}(\text{acac})]\text{PF}_6$	0.142	-	0.159	1.01
$[\text{CuLi}^{2(S)}(\text{acac})]\text{PF}_6$	0.166	-	0.106	0.96
Kang Zheng (2014)³⁸				
$[\text{Cu}_2(\text{pdmaox})\text{Cl}(\text{CH}_3\text{OH})(\text{dabt})]\text{CH}_3\text{OH}$	0.87	0.87	0.383	0.9659
$[\text{Cu}_2(\text{pdmaox})(\text{bpy})(\text{H}_2\text{O})]-(\text{pic})\cdot\text{H}_2\text{O}$	1.18	1.18	0.523	0.9836

Table S3 IC_{50} values (μM) obtained with different cell lines for 48 h.

Complex	IC_{50} (μM)			
	HeLa	MCF-7	A549	BEAS-2B
1	24.5 ± 1.4	25.0 ± 2.2	46.2 ± 2.3	22.7 ± 0.5
2	> 100	63.6 ± 4.2	> 100	> 100
Cisplatin	4.3 ± 0.05	4.7 ± 0.5	14.8 ± 1.3	3.2 ± 0.01